RxDoctor Payments Data

Matthew Johnson, DO

Psychiatry · Lansing, MINPI 1558920330

Payments from drug & device makers

$3,624in general payments, 2019–2025

Across 121 payments — averaging $29.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$959
  • Otsuka America Pharmaceutical, Inc.$571
  • AbbVie$494
  • Johnson & Johnson$380
  • E.r. Squibb & Sons, L.L.C.$335
  • Alkermes, Inc.$312
  • plus $573 from 7 others

What the payments were for

  • Food & beverage$3,624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,624 in reported general payments places this provider in the 85th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$26,264
Medicare patients
45
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$33,455
AuvelityDextromethorphan Hbr/Bupropion11$13,302
Paliperidone ErPaliperidone12$3,291
Quetiapine Fumarate ErQuetiapine Fumarate14$3,085
Duloxetine Hcl21$2,492
Aripiprazole13$983
Bupropion XlBupropion Hcl19$686
Trazodone Hcl44$274
Lamotrigine33$186
Hydroxyzine Pamoate17$183
Venlafaxine Hcl ErVenlafaxine Hcl12$164
Sertraline Hcl25$125
Quetiapine Fumarate24$108
Buspirone Hcl11$108
Escitalopram Oxalate16$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$380$33,45512 claims
Axsome Therapeutics, Inc.Auvelity$62$13,30211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →